Profile data is unavailable for this security.
About the company
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
- Revenue in JPY (TTM)311.30m
- Net income in JPY-975.80m
- Incorporated2015
- Employees28.00
- LocationNoile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
- Phone+81 358437819
- Websitehttps://www.noile-immune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FunPep Co Ltd | 676.00k | -760.40m | 4.06bn | 15.00 | -- | 1.72 | -- | 6,002.03 | -31.52 | -31.52 | 0.028 | 90.56 | 0.0002 | -- | 3.39 | 45,066.67 | -26.86 | -27.10 | -28.42 | -28.75 | -- | -- | -112,484.90 | -815.82 | 17.27 | -1,006.15 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kringle Pharma Inc | 77.93m | -904.81m | 4.21bn | 13.00 | -- | 1.79 | -- | 53.97 | -159.92 | -159.92 | 13.58 | 356.64 | 0.027 | -- | 2.80 | 5,994,308.00 | -31.29 | -19.00 | -33.20 | -20.23 | -- | -- | -1,161.12 | -156.51 | 12.85 | -- | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
| Perseus Proteomics Inc | 100.40m | -1.10bn | 4.35bn | 24.00 | -- | 2.84 | -- | 43.30 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | -- | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | -- | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Renascience Inc | 194.17m | -258.34m | 4.53bn | 3.00 | -- | 2.82 | -- | 23.31 | -20.32 | -20.32 | 15.27 | 126.40 | 0.089 | -- | -- | -- | -11.84 | -- | -12.49 | -- | 85.31 | -- | -133.05 | -- | -- | -- | 0.1814 | -- | 93.11 | -- | 23.07 | -- | -- | -- |
| Immuno-Biological Laboratories Co., Ltd. | 816.70m | 186.69m | 4.64bn | 60.00 | 24.84 | 3.67 | -- | 5.68 | 20.05 | 20.05 | 87.69 | 135.86 | 0.535 | 0.9358 | 4.53 | -- | 12.23 | -13.97 | 14.68 | -16.39 | 63.34 | 57.73 | 22.86 | -39.23 | 3.65 | -- | 0.1572 | -- | 2.78 | 0.8924 | 164.44 | -- | -- | -- |
| Kidswell Bio Corp | 2.43bn | -1.42bn | 4.81bn | 41.00 | -- | 5.71 | -- | 1.98 | -40.81 | -40.81 | 68.79 | 21.35 | 0.5415 | 1.84 | 2.47 | -- | -31.67 | -57.41 | -51.25 | -81.13 | 42.75 | 55.20 | -58.49 | -123.52 | 1.70 | -28.91 | 0.7559 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| KAINOS Laboratories, Inc. | 5.06bn | 637.97m | 5.19bn | 144.00 | 7.47 | 0.7656 | 6.86 | 1.03 | 152.41 | 152.41 | 1,206.78 | 1,486.43 | 0.6053 | 3.08 | 4.55 | -- | 7.64 | 6.92 | 9.96 | 9.26 | 50.46 | 51.84 | 12.62 | 10.80 | 2.43 | -- | 0.1221 | 18.46 | 2.71 | 1.60 | 12.28 | 10.57 | -9.83 | 16.36 |
| Noile-Immune Biotech Inc | 311.30m | -975.80m | 5.46bn | 28.00 | -- | 1.02 | -- | 17.53 | -22.56 | -22.56 | 7.19 | 123.55 | 0.0658 | 0.139 | 5.07 | 11,118,000.00 | -20.62 | -- | -21.29 | -- | 99.55 | -- | -313.45 | -- | 52.74 | -805.65 | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| Solasia Pharma KK | 408.00m | -1.18bn | 5.80bn | 24.00 | -- | 3.00 | -- | 14.23 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| DNA Chip Research Inc | 490.46m | -248.29m | 6.15bn | 36.00 | -- | 8.40 | -- | 12.54 | -39.09 | -39.09 | 77.17 | 108.27 | 0.5292 | 9.84 | 3.11 | -- | -26.79 | -23.49 | -32.60 | -26.70 | 13.53 | 14.28 | -50.62 | -54.10 | 2.92 | -2,206.97 | -- | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Cyfuse Biomedical KK | 64.79m | -645.40m | 6.16bn | 21.00 | -- | 2.00 | -- | 95.00 | -82.27 | -82.27 | 8.26 | 378.39 | 0.0153 | 0.5202 | 13.80 | 3,085,095.00 | -15.19 | -- | -17.68 | -- | 61.81 | -- | -996.19 | -- | 6.39 | -81.61 | 0.2126 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| Chiome Bioscience Inc | 642.70m | -1.30bn | 6.37bn | 51.00 | -- | 5.05 | -- | 9.91 | -25.56 | -25.56 | 12.60 | 22.39 | 0.3348 | 4.27 | 8.96 | 12,602,040.00 | -67.53 | -50.50 | -88.83 | -57.38 | 55.96 | 57.53 | -201.70 | -224.74 | 3.46 | -629.88 | 0.2009 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
| MEDRx Co Ltd | 22.57m | -770.66m | 6.37bn | 22.00 | -- | 3.03 | -- | 282.31 | -20.97 | -20.97 | 0.6128 | 47.84 | 0.0143 | 0.00 | 4.22 | 1,025,955.00 | -48.80 | -58.15 | -50.27 | -62.23 | 100.00 | 95.70 | -3,414.38 | -1,526.17 | 43.57 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 30.75bn | -180.00m | 6.74bn | 872.00 | -- | 0.309 | 5.76 | 0.2191 | -49.89 | -49.89 | 8,520.20 | 5,115.78 | 0.6268 | 2.14 | 2.70 | -- | -0.3689 | 0.7482 | -0.5204 | 1.08 | 25.17 | 30.99 | -0.5887 | 1.13 | 1.53 | -- | 0.4791 | 50.33 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| Carna Biosciences, Inc. | 1.58bn | -1.03bn | 6.76bn | 67.00 | -- | 1.92 | -- | 4.28 | -60.32 | -60.32 | 92.24 | 205.19 | 0.3574 | 1.24 | 12.63 | 23,578,990.00 | -23.36 | -14.45 | -25.26 | -16.95 | 89.03 | 90.59 | -65.36 | -35.42 | 13.18 | -- | 0.0326 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 6.84bn | 109.00 | -- | 0.9528 | -- | 1.47 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
Data as of May 28 2024. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY
0.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 28 Jun 2023 | 130.10k | 0.30% |
| Simplex Asset Management Co., Ltd.as of 09 May 2024 | 48.70k | 0.11% |
| Federated Equity Management Company of Pennsylvaniaas of 31 Dec 2023 | 0.00 | 0.00% |
Data from 31 Mar 2024 - 23 May 2024Source: FactSet Research Systems Inc.
